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from the average HR for the overall SA population (74 bpm) could reduce SUS direct 
cost by over R$450 million. CONCLUSIONS: These results show that effective lower-
ing heart rate strategies may contribute to substantial savings of public funds in Brazil. 
Therefore, heart rate must be regarded as an important CV risk factor from an eco-
nomic point of view.
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OBJECTIVES: To assess the cost effectiveness of rivaroxaban against enoxaparin for 
the prevention of venous thromboembolism (VTE) in patients undergoing total hip 
replacement (THR) or total knee replacement (TKR) in a Colombian setting. 
METHODS: A cost-effectiveness model was developed to assess the cost effectiveness 
of rivaroxaban compared to enoxaparin in a Colombian setting over a 5-years time 
horizon. The model was divided into three modules: prophylaxis, post-prophylaxis, 
and long-term complications. The ﬁrst two modules constitute the acute phase and 
were represented in a decision tree while the long-term complications module was 
developed as a Markov process. Efﬁcacy and safety parameters used in the prophylaxis 
module were derived from the RECORD trials in the prevention of VTE following 
THR or TKR. Published epidemiological and clinical data were used to estimate the 
risk of VTE and other long term complications beyond the trial period. The analysis 
was performed from a health care payer’s perspective. Cost data was based on clinical 
guidelines, product labels, nationally and locally published sources, and expert 
opinion. VTE related utilities reported in literature were used in this analysis. One-way 
and probabilistic sensitivity analyses were performed in order to address uncertainty 
around the model inputs. RESULTS: Rivaroxaban dominated enoxaparin, yielding 
improved health outcomes (QALYs) and savings of COP 114,345 per patient in THR. 
Savings were driven mainly by reduced outpatient administration costs. Rivaroxaban 
also dominated enoxaparin with savings of 152,484 COP in TKR patients. Probabi-
listic sensitivity analyses showed dominance in 89% of cases in THR and in 99% in 
TKR. CONCLUSIONS: Rivaroxaban is a cost-effective alternative to enoxaparin for 
the prevention of VTE following THR or TKR in Colombia.
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OBJECTIVES: To develop a cost-effectiveness analysis of dabigatran etexilate versus 
enoxaparin for the prevention of venous thromboembolism after total hip replacement 
under the Brazilian public health care system perspective. METHODS: A decision tree 
analysis was developed for the ﬁrst 180 days, considering the occurrence of deep vein 
thrombosis (DVT), pulmonary embolism (PE) and all-cause mortality, followed by 
two Markov models, for post-thrombotic syndrome and thromboembolic pulmonary 
hypertension. Long term costs and outcomes associated with the prevention of venous 
thromboembolism in patients receiving dabigatran or enoxaparin were, therefore, 
projected. The cycle duration was 1 month and the corresponding transition probabili-
ties were obtained from the RE-NOVATE study. The outcomes were expressed as the 
incremental number of all thromboembolic events and deaths related to the surgical 
procedure and its acute and late complications. The analysis considered only direct 
medical costs. Unit costs for drugs and procedures were obtained from Kairos 
 Magazine (ex-factory price) and the National Database of Ambulatory Costs 
(SIA/DATASUS), respectively. Costs and outcomes were discounted at an annual 5% 
discount rate. A budget impact analysis was developed, considering the estimated 
number of total hip arthroplasties in the Brazilian public health care system in 2009. 
Main parameters were evaluated in a sensitivity analysis. RESULTS: After a literature 
review, the evidences showed similar effectiveness between both treatments. Total 
costs associated with dabigatran and enoxaparin were BRL667 (US$476) and 
BRL1,097 (US$784), respectively. The prophylaxis cost reduction was BRL430 
(US$307), in favor of dabigatran. In 2009, total annual costs estimated for dabigatran 
and enoxaparin were BRL7,425,815 (US$5,304,154) and BRL12,222,284 
(US$8,730,203), respectively, with a negative budget impact of BRL4,796,469. (2005 
purchasing power parity index 1USD  1.4BRL) CONCLUSIONS: Dabigatran 
showed to be as effective as enoxaparin and cost-saving for the prevention of venous 
thromboembolism after total hip replacement under the Brazilian public health care 
system perspective.
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OBJECTIVES: This study was designed to evaluate the cost-effectiveness of diagnostic 
assessment guided to B-Type Natriuretic Peptide compared with clinical judgment 
alone, in acute dyspnea, in the Uniﬁed Health System Scenario. METHODS: A Deci-
sion Analytic Model was developed to evaluate the cost-effectiveness of diagnostic 
assessment guided to B-Type Natriuretic Peptide compared with clinical judgment 
alone. We used effectiveness data described in a randomized, controlled clinical trial 
and data from ambulatory and hospital treatment costs coming from Brazilian studies 
on costs of Heart Failure. The effectiveness units were “hospital admissions avoided” 
and “echocardiography avoided”, at 60 days. The decision tree and statistical analyses 
were performed by the software TreeAge Pro Healthcare. RESULTS: The use of B-
Type Natriuretic Peptide in the diagnostic assessment of patients with acute dyspnea 
showed a reduction of echocardiography (-58.2%) and hospital admissions (-12.6%), 
when compared to the clinical judgment alone. The average cost per patient of B-Type 
Natriuretic Peptide group was BRL 652 (US$465) versus BRL 659 (US$470) of clinical 
group (2005 purchasing power parity index 1 USD  1.4 BRL*). CONCLUSIONS: 
We concluded that use of B-Type Natriuretic Peptide can be cost saving strategy, in 
the diagnostic assessment of patients presenting to acute care settings with dyspnea, 
in Uniﬁed Health System.
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OBJECTIVES: Clinical evidence has demonstrated that considerable differences exist 
among various ARBs in terms of safety and efﬁcacy. These differences can lead to 
diverse economic outcomes depending on the chosen intervention. This analysis was 
aimed to assess the cost-effectiveness of ARBs available in the Colombian market. 
METHODS: We performed a cost-effectiveness ratio analysis of ARBs in Colombia. 
A systematic review was performed on available evidence. Head-to-head studies com-
paring Irbesartan with other ARBs were included and costs were evaluated based on 
a Colombian pricelist publication. Cost-effectiveness ratio was ﬁnally calculated with 
the efﬁcacy of interventions (systolic and diastolic mmHg reduction) in the analyzed 
trials. A sensitivity analysis was performed. RESULTS: Based on Mancia et al. 
[BloodPressMonit 2002;7: 135–42] and drug cost in the Colombian market, cost-
effectiveness for Irbesartan 150 mg was U$10.42 per mmHg reduced in systolic blood 
pressure (SBP) and US$18 for diastolic blood pressure (DBP) compared with US$18.53 
in DBP and US$28.72 for SBP with Valsartan (80 mg). According to Bobrie et al. 
[AmJHypertens 2005;18:1482–8] the cost effectiveness ratio for Irbesartan/Hydro-
chlorothiazide was US$8.97 (SBP) and US$12.28 (DBP) per mmHg reduced compared 
with US$12.72 (SBP) and US$18.22 (DBP) for Valsartan/Hydrochlorothiazide. The 
results based on Oparil et al. [JClinH 2001;3:283–318] were US$13.26 (SBP) U$17.81 
(DBP) for Irbesartan 150 mg compared with U$19.09 (SBP) US$28.27 (DBP) for 
Losartan 50 mg. Results from analysis performed with Kassler-Taub [AJH 
1998;11:445–53] were US$820 (SBP) and U$11.50 (DBP) for Irbesartan 300 mg 
compared with US$13.41 (SBP) and $17.41 (DBP) for Losartan 100 mg. Finally, based 
on the Negro et al. [JEndocrinolInvest. 2006;29:957–61] the results were $23.02 (SBP) 
and US$30.42 (DBP) compared with US$27.95 (SBP) US$32.67 (DBP) for Telmisartan 
80 mg. CONCLUSIONS: This analysis shows that ARBs have different economic 
outcomes regarding hypertension treatment. Irbesartan shows a good cost-effective-
ness ratio compared with other ARBs in the Colombian context.
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OBJECTIVES: To develop a cost-effectiveness analysis of dabigatran etexilate versus 
enoxaparin for the prevention of venous thromboembolism after total knee replace-
ment, under the Brazilian public health care system perspective. METHODS: A deci-
sion tree analysis was developed for the ﬁrst 180 days, considering the occurrence of 
deep vein thrombosis (DVT), pulmonary embolism (PE) and all-cause mortality, fol-
lowed by two Markov models, for post-thrombotic syndrome and thromboembolic 
pulmonary hypertension. Long term costs and outcomes associated with the preven-
tion of venous thromboembolism in patients receiving dabigatran or enoxaparin were, 
therefore, projected. The cycle duration was 1 month and the corresponding transition 
probabilities were obtained from the RE-MODEL study. The outcomes were expressed 
as the incremental number of all thromboembolic events and deaths related to the 
surgical procedure and its acute and late complications. The analysis considered only 
direct medical costs. Unit costs for drugs and procedures were obtained from Kairos 
Magazine (ex-factory price) and the National Database of Ambulatory Costs 
(SIA/DATASUS), respectively. Costs and outcomes were discounted at an annual 5% 
discount rate. A budget impact analysis was developed, considering the estimated 
number of total knee arthroplasties in the Brazilian public health care system in 2009. 
Main parameters were evaluated in a sensitivity analysis. RESULTS: After a literature 
review, the evidences showed similar effectiveness between both alternatives. Total 
costs associated with dabigatran and enoxaparin were BRL279 (US$199) and BRL451 
(US$322), respectively. The prophylaxis cost reduction was BRL172 (US$123), in 
favor of dabigatran. In 2009, total annual costs estimated for dabigatran and enoxa-
parin were BRL1,113,412 (US$795,294) and BRL1,800,886 (US$1,286,347), respec-
tively, with a negative budget impact of BRL687,474 (US$491,053). (2005 purchasing 
power parity index 1USD  1.4BRL) CONCLUSIONS: Dabigatran showed to be as 
